Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Ivarmacitinib effectively regrows hair in severe alopecia areata.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

This project reports that Vitex rotundifolia may have cancer chemotherapeutic potential due to its ability to inhibit MAP kinase phosphorylation, suggesting further investigation into its active constituents.

This review discusses current treatments for discoid lupus erythematosus and highlights anifrolumab as a promising option for difficult cases, but no new clinical results are reported.

This study suggests that long-term treatment with the contact sensitizer SADBE in mice may reduce leucocyte traffic in alopecia areata through impaired leucocyte extravasation.

This article reviews adverse drug reactions, emphasizes methods of prevention, and encourages reporting to the FDA's medWatch program, but presents no new study findings.

This review examines the phytochemistry, biological activities, and potential applications of Akebia species in medicine and cosmetology, highlighting the differences in chemical composition between A. quinata and A. trifoliata.

This study described a case where both alopecia universalis and Crohn's ileitis in a 23-year-old man showed remarkable improvement with the JAK1 inhibitor upadacitinib, highlighting its potential as a treatment for patients with concurrent conditions.

This review highlights the potential of drug-loaded extracellular vesicles as a promising drug delivery platform but notes that clinical translation faces challenges due to variability in methods and the need for standardization and safety evaluation.

This paper does not provide study results; it shares author affiliations and publication details without reporting any findings.

This case study reports that adding adalimumab to a 12-year-old VKH patient's treatment allowed for ocular inflammation remission, vision improvement, and corticosteroid tapering, suggesting escalation of immunosuppression may be critical in pediatric VKH cases.

This study identified 11 previously unreported ABCA12 variants associated with varying severities of autosomal recessive congenital ichthyoses and expanded the phenotype spectrum of ichthyosis linked to these variants.

This study found that co-drugs synthesized from hydroquinone and tranexamic acid improved skin targeting and deposition, with reduced irritation and enhanced efficacy for treating hyperpigmentation.

CaBP1 and CaBP2 are necessary for proper hearing and neurotransmission in the ear's inner hair cells.

In this case report, a patient with diffuse alopecia areata experienced complete hair regrowth after treatment with oral abrocitinib, with no adverse effects observed.

CaBP1 and CaBP2 are necessary for proper hearing and neurotransmission in the ear's inner hair cells.

This study reports that two phase III trials demonstrated the effectiveness of the oral Janus kinase inhibitor baricitinib at 2 mg or 4 mg daily for treating severe alopecia areata in adults, marking a potential advance in managing this condition.

This study demonstrated that a microarray patch can deliver antibodies in a controlled and prolonged manner, maintaining their functionality after manufacturing and heat exposure, with successful pharmacokinetic proof-of-concept in rats.

This study reports a notable case of a patient with psoriatic arthritis and alopecia universalis who experienced significant improvement in both conditions after treatment with the JAK1 selective inhibitor upadacitinib, suggesting its potential efficacy for alopecia universalis, especially in cases involving inflammatory arthritis.

This report describes the 2024 American Academy of Dermatology Annual Meeting in San Diego, notable for attracting nearly 20,000 attendees with 339 sessions covering a wide range of dermatological topics, making it potentially the largest dermatology meeting by attendance.

This article discusses the potential of intralesional cidofovir as a treatment for SCC and reports no systemic toxicity, but highlights surgical excision as the most reliable curative option.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

This case report describes a rare instance of alopecia universalis occurring eight weeks after discontinuing pegylated interferon α and ribavirin therapy, highlighting the need for awareness among healthcare providers.

This study reports a case where a patient with rheumatoid arthritis and alopecia areata saw significant improvement in both conditions after switching to daily upadacitinib treatment, specifically achieving complete hair regrowth within six months.

This case series observed that patients with persistent post-COVID-19 symptoms reported considerable improvement after using icosapent ethyl, suggesting potential therapeutic success warranting further research.

This study found that daily use of an emollient PLUS containing ADE-G1 significantly reduced xerosis severity and improved quality of life in cancer patients, regardless of their initial xerosis severity or cancer treatment.